Cargando…
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity....
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6544598/ https://www.ncbi.nlm.nih.gov/pubmed/30993606 http://dx.doi.org/10.1007/s40268-019-0269-9 |